SCHEMBL232855

SCHEMBL232855

C/C=C/C(=O)NCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.45
POLB P06746 1/20 0.44
EGLN1 Q9GZT9 2/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
PTGS2 P35354 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TGM2 P21980 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CTH P32929 1/20 0.38
APEX1 P27695 1/20 0.36
ECE1 P42892 1/20 0.35
FAAH O00519 1/20 0.35
ITGB3 P05106 1/20 0.35
ITGB1 P05556 1/20 0.35
ITGAV P06756 1/20 0.35
ITGA5 P08648 1/20 0.35
PLA2G2A P14555 1/20 0.34
MME P08473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232856 1.00 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2POLBEGLN1MAPT
SCHEMBL820926 0.85
SCHEMBL11100545 0.85
SCHEMBL820925 0.85
SCHEMBL9480613 0.85 CNR2 (0.50) ALDH1A1SMN1; SMN2POLBEGLN1MAPT
SCHEMBL23140079 0.81 TGM2 (0.40) ALDH1A1SMN1; SMN2POLBTGM2APEX1
SCHEMBL23140062 0.81 TGM2 (0.40) ALDH1A1SMN1; SMN2POLBTGM2APEX1
SCHEMBL2159350 0.80
SCHEMBL24703252 0.79 TGM2 (0.39) ALDH1A1SMN1; SMN2TGM2APEX1CNR2
SCHEMBL10810547 0.79 TGM2 (0.39) ALDH1A1SMN1; SMN2TGM2APEX1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113325110-A Method for determining specific organic acid by tandem mass spectrometry 浙江大学 2021-08-31 CN claimed
CN-113156096-A Blood-based biomarkers for diagnosing coronary atherosclerotic disease 全球基因集团有限责任公司 2021-07-23 CN claimed
CN-106537145-B Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment 麦特博隆股份有限公司 2020-08-25 CN claimed
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH UNIV CALIFORNIA (US) 2026-03-19 US disclosed
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM UNIV CALIFORNIA (US) 2025-12-11 US disclosed
CN-115677718-B Methyl methylamine derivative preparation, pharmaceutical composition and application thereof 武汉思瓴生物科技有限公司 2024-11-01 CN disclosed
US-11850440-B2 Therapeutic systems using magnetic fields UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2023-12-26 US disclosed
CN-116672408-A Application of Xinkuanning preparation in preparing medicine for treating arrhythmia and lipid metabolism abnormality 陕西摩美得气血和制药有限公司 2023-09-01 CN disclosed
CN-116194197-A Resin composition for gas separation membrane and gas separation membrane 住友化学株式会社 2023-05-30 CN disclosed
CN-116133740-A Gas separation membrane and method for producing same 住友化学株式会社 2023-05-16 CN disclosed
CN-115677718-A Methylmethylamine derivative preparation, pharmaceutical composition and application thereof 武汉思瓴生物科技有限公司 2023-02-03 CN disclosed
US-20120004854-A1 METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF GEORGIA TECH RESEARCH CORPORATION 2012-01-05 US disclosed
US-7993931-B1 Oxygen-18 labeled organic acids and use in diagnosing metabolic disorders QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) 2011-08-09 US disclosed
WO-2011049150-A1 PYRONE COMPOUND AND ITS USE FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-28 WO disclosed
WO-2011049150-A1 PYRONE COMPOUND AND ITS USE FOR PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-28 WO disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed
US-5342766-A Culturing microorganism in an aqueous solution containing source of carbon, nitrogen and inorganic salts, recovering TORAY INDUSTRIES, INC. (JP) 1994-08-30 US disclosed
EP-0243496-A1 PROCESS FOR PRODUCING L-THREONINE BY FERMENTATION TORAY INDUSTRIES, INC. (JP) 1987-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM CYP27A1, LIPC, CYP46A1 ALDH1A1 1661/4885SMN1; SMN2 4332/4885POLB 1663/4885
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH IDO1, INMT, IDO2 ALDH1A1 938/4885SMN1; SMN2 1923/4885POLB 4458/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 ALDH1A1 2376/4885SMN1; SMN2 4563/4885POLB 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.